When you buy the MiniMed™ 670G system today, you’ll automatically be entered into the Next Tech Pathway program which will help you access our next technology when it's released. The last day to place an order and be enrolled in the program is April 1, 2020.
Our pump and continuous glucose monitor (CGM) work together to:
We are working hard on developing new technology. Our goals for upcoming devices are to:
The Next Tech Pathway program is available to those that purchase a MiniMed™ 670G system and meet one of the following requirements:
- New to Medtronic insulin pump therapy
- Upgrade from an out-of-warranty pump
Your out-of-pocket cost will vary based on your insurance provider and how much you’ve paid so far towards your deductible. If you fill out our form, a therapy specialist will reach out to discuss your options and estimated costs.
It can take several weeks to complete a purchase. However, we will work with your insurance plan and healthcare professional to process your order as quickly as possible. To help speed up the process, we recommend connecting with your doctor as soon as possible about starting on our therapy.
Δ Refers to Auto Mode. Some user interaction required. Individual results may vary.
# Based on sensor glucose.
1. Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–1408.
Φ The patient testimonials above relate an account of an individual’s response to treatment. The account is genuine, typical and documented. However, this patient’s response does not provide any indication, guide, warranty or guarantee as to the response other people may have to the treatment. The response other individuals have to the treatment could be different. Responses to the treatment can and do vary. Not every response is the same. Please talk to your doctor about your condition and the risks and benefits of these technologies. Sage was compensated for spending the day with us and allowing us to photograph her. Her thoughts and opinions are herown. Individual results may vary.
Terms and Conditions
The Next Tech Pathway program (the “Program”) allows eligible, enrolled participants whose MiniMed™ 670G system order is shipped starting on 11/7/19 to be included. The last day to place an order is 4/1/20. This Program allows for an upgrade to our next MiniMed™ system at $0. Eligibility dates subject to change.
To be eligible for the Program, participants must purchase a MiniMed™ 670G system and meet one of the following requirements:
This program is not available to customers on a rental program such as those enrolled in federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense (“DoD”) or TRICARE.To upgrade through the Program, all participants must agree and are subject to these terms and conditions:
Important Safety Information: MiniMed™ 670G System with SmartGuard™ technology
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
© Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.